An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. - Wikidata - awgldk - TriplyDB

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

http://www.wikidata.org/entity/Q37698249

about

Interventions for treating pulmonary hypertension in people with sickle cell disease or thalassaemia Treatment-related biomarkers in pulmonary hypertension Biomarkers and recent advances in the management and therapy of sickle cell disease Advances in sickle cell therapies in the hydroxyurea era Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis.Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.Pulmonary hypertension in Nigerian adults with sickle cell anemia.Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review.Update on the use of hydroxyurea therapy in sickle cell disease Peroxisome proliferator-activated receptor-α-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1α The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.Vasculopathy and pulmonary hypertension in sickle cell disease.Doppler-Defined Pulmonary Hypertension in Sickle Cell Anemia in Kurdistan, Iraq.Update in Pulmonary Vascular Diseases 2014.Leukocyte expression of heme oxygenase-1 [hmox1] varies inversely with severity of tricuspid regurgitation in acute pulmonary embolism Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease.Pathophysiology and treatment of pulmonary hypertension in sickle cell disease Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension.Early detection of pulmonary arterial hypertension.Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.Chronic Pulmonary Complications of Sickle Cell Disease.Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence.A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia.Pulmonary hypertension among 5 to 18 year old children with sickle cell anaemia in Nigeria.Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease.Erythroid DAMPs drive inflammation in SCD.[Hemoglobin disorders].Pulmonary hypertension in sickle cell disease Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease.Ironing out placenta growth factor Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption.Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease.Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.Successful pulmonary thromboendarterectomy in a patient with sickle cell disease and associated resolution of a leg ulcer.Renin-angiotensin system blockade promotes a cardio-renal protection in albuminuric homozygous sickle cell patients.Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study.

P2860

Q24187475-E84F0FB0-0885-4E8E-B865-ADD3A8D7ACA2 Q28081276-A165BA22-31EB-4B7D-B158-B01CBEC0A7CD Q28082462-DA873EA7-7722-4209-85F0-8F182566DB84 Q28088552-3D1CA8B0-4A83-4FF3-B779-9063F982EE25 Q28395387-4079FC8F-81F9-4239-8E93-382E318F3912 Q30250302-DF03749C-9908-47FD-974D-C644A56233FD Q33574142-27DAEE67-D65E-47E5-A33C-28E8A93A22DB Q33674097-288E64F1-278A-439F-AB65-0DB6EDE647D1 Q34470834-2B1FCD98-FA4B-468F-BA39-5B2D38E86F9D Q34737460-A7315828-DF15-4559-877D-784F73D1095C Q34774521-205AEC7A-166F-4482-B787-06A076DCECC8 Q34924892-182AE071-1990-46F3-BF7F-434CF808575E Q35086394-1E93CF82-579A-4ED4-8592-9CAE3F97F369 Q36119758-D50DC959-265E-4233-B334-20C47E3E87A2 Q36128639-94A837F5-B6F3-4FE0-831C-115C77A2DF24 Q36387965-D2F56FF3-D018-406A-884D-68B3E8D3AE44 Q36470075-6D2036AF-A123-4680-AEE8-C647A78E4C14 Q36596861-48F72E18-0729-44F3-A77A-3C58289C7026 Q37258558-156A786A-D24B-441E-AE8C-AFEDB6DE1595 Q37354098-F678738E-FBD5-4859-8D14-C9747650B24C Q38271027-0B2C6363-56D4-4DBF-BD13-883FDD6C3C97 Q38682842-B3BB3659-E293-4E5D-B249-3E2272045C3C Q38719970-6BACA89D-5CEF-485C-B821-E5513AFCAAD9 Q38813089-EF6C1960-1258-4E91-8F84-781138219AC9 Q39269713-9A902071-E7BE-4C52-8316-5230425C3488 Q40041292-AB026FDC-DFD5-45A9-84FD-50B99E97D9DD Q40496218-4D7CC450-13B1-4A67-8594-CECF090F63F6 Q40650786-5BD45AC0-7799-474E-B361-CB6CE58DB9AB Q41661793-0EAE1D5F-729D-401F-90E4-B093E670A3BE Q41963738-C8CB34F1-9934-4E9B-AACE-A8A772013303 Q42632177-AA6E0F0B-C371-4BDF-973B-F0C5B26555F5 Q42651980-3132A64E-F76E-4B57-AE3C-07E4B4504B50 Q42778192-489A8A40-8AED-4645-BEDA-A4A28CE7E03D Q42993235-698D5E70-A5EA-4CBD-9707-82F1D11DF001 Q46865136-47CCBCBB-DD19-4FE2-8BFC-287377102E99 Q47103242-8D6FEEC2-0FF6-48BD-A9B4-B2866905AD29 Q47646806-80896967-57A9-4456-B41E-AF2E8B7A116B Q47763028-1DEC3A52-BCDF-41C2-9B1C-5C153FA75E1F Q47799282-9EA8EC89-5083-4EF3-BD47-D52AD843535E Q48140774-7CDC87EE-D922-430C-AC9B-44F95E783B8A

P2860

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

http://www.wikidata.org/entity/Q37698249

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

An official American Thoracic ...... ension of sickle cell disease.

@en

An official American Thoracic ...... ension of sickle cell disease.

@nl

type

label

An official American Thoracic ...... ension of sickle cell disease.

@en

An official American Thoracic ...... ension of sickle cell disease.

@nl

prefLabel

An official American Thoracic ...... ension of sickle cell disease.

@en

An official American Thoracic ...... ension of sickle cell disease.

@nl

P1433

Q37698249-39EF7BB7-9594-44FB-9CB6-1D9407DEEFC9

P1476

Q37698249-6FCA5A99-D5BD-444C-A274-8C04EF602D6C

P2093

Q37698249-20060CD3-D4AF-4B33-8041-5E8DD3800B6B

Q37698249-39B2CC13-7DE8-4896-9042-5E6C250A51B0

Q37698249-41BC5DE0-DCC0-47BF-8B30-37CFE244CBB7

Q37698249-567CBC10-04C9-41DE-A883-B0772A689FB4

Q37698249-60A81133-16DD-47D4-885E-F29085850E40

Q37698249-88BE44A6-503F-4594-AC3D-E2C110434941

Q37698249-8EE7AF59-3FBB-42EF-86B5-C5615550FBBC

Q37698249-AB2F5337-506D-437A-AD11-8A261B481975

Q37698249-B76D085E-BBB3-4FB0-B6E5-90EDB3C7E8EF

Q37698249-BA15D9D3-81B6-42CF-98A8-EF37F117C0B6

P2860

Q37698249-08997FB7-FB63-471B-938C-0CFF2E47B299

Q37698249-10779C89-1F26-4D92-9B73-6ED5721EBC8B

Q37698249-118FE256-9C4B-44A3-A3D0-BB877A517F3D

Q37698249-12FD94D7-94EB-49F5-93F8-A8378EF2FD26

Q37698249-162E1427-94E4-496E-AEBF-E27C8EDF3AFA

Q37698249-189138CD-0D43-4AEA-A251-1680B63172C8

Q37698249-1E58E559-C2DF-4C99-8E2C-E1657C49D09A

Q37698249-1F59E7AA-06EF-4A45-8BF9-3626388A9107

Q37698249-278F1F39-B23D-48D0-B22F-7CACB25A0F5D

Q37698249-33868736-5AD6-4D6A-ACEF-41304AB743A0

P304

Q37698249-34E1C1C6-E64D-4415-88F8-245D122C9576

P31

Q37698249-D717385F-FF3F-416B-87A4-B49B2EAFD052

P356

Q37698249-1A5822AD-3579-4D34-A270-F1655E14F50C

P407

Q37698249-4384E062-33F5-4F55-8433-D4E094D54F24

P433

Q37698249-EC332C2F-30DD-442A-A0FD-B3577CF7C356

P478

Q37698249-93C07550-BE43-4AC8-AFA7-20F7DC1DB68C

P50

Q37698249-055E5FED-FA2F-47BC-8515-5957AE24FCF8

Q37698249-0CD85A31-7A95-4113-960D-33308F76F417

Q37698249-5D12041E-B023-4F00-A98B-6BA2950C3D4A

Q37698249-60AF6ADC-6B32-4896-946A-B0F17FDA6421

Q37698249-6332ADB6-051C-458C-A7FB-5286FBD31D35

P577

Q37698249-97B8CFC9-7F46-4A8D-BA03-40AA9933A35A

P698

Q37698249-2E7B6462-11AA-46B3-8E5D-F9E314F76974

P921

Q37698249-21B8243A-5F0B-4C48-B0CF-B99FC4239F07

Q37698249-68BD7A02-1ADA-47AB-81C9-C2B2B32BF760

Q37698249-8f02bbe2-e0fe-4545-b32e-b55714fbdd89

P932

Q37698249-1D89700E-9782-436F-B5B1-4DF855E5FCE2

P356

RCCM.201401-0065ST

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

An official American Thoracic ...... ension of sickle cell disease.

@en

P2093

American Thoracic Society Ad H ...... tension of Sickle Cell Disease

http://www.w3.org/2001/XMLSchema#string

Claudia R Morris

http://www.w3.org/2001/XMLSchema#string

David B Badesch

http://www.w3.org/2001/XMLSchema#string

Elizabeth S Klings

http://www.w3.org/2001/XMLSchema#string

J Simon Gibbs

http://www.w3.org/2001/XMLSchema#string

Kamal K Mubarak

http://www.w3.org/2001/XMLSchema#string

Kenneth I Ataga

http://www.w3.org/2001/XMLSchema#string

Kevin C Wilson

http://www.w3.org/2001/XMLSchema#string

Lakshmanan Krishnamurti

http://www.w3.org/2001/XMLSchema#string

Laura M Decastro

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelin receptor antagonists for pulmonary arterial hypertension

Phosphodiesterase 5 inhibitors for pulmonary hypertension

Prostacyclin for pulmonary hypertension in adults

Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results

Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

P304

727-740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201401-0065ST

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P50

Martin H Steinberg

Gregory J. Kato

Erika Berman-Rosenzweig

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24628312

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

arterial hypertension

P932

3983842

http://www.w3.org/2001/XMLSchema#string